Related Experiment Video
Updated: Jun 1, 2025

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
Published on: November 11, 2022
Navigating Hyperkalaemia- The A-to-H Clinical Strategy
Sourabh Sharma1, Sanjay Kalra2
1Department of Nephrology, VMMC & Safdarjung Hospital, New Delhi, India.
Hyperkalaemia is a life-threatening dyselectrolytaemia which is characterized by elevated serum potassium levels. It needs a systematic and overarching approach to effectively manage a case of hyperkalaemia. We propose a structured A-to-H approach to guide clinicians in managing hyperkalaemia, ensuring that no critical aspect is neglected or inadvertently missed. This approach involves Analytical accuracy, Background, Clinical context, Diagnosis and drugs, Evaluation, Follow-up, Guidelines adherence, and Health education. With this article, we reiterate the need to properly assess and promptly manage a case of hyperkalaemia in various clinical settings, providing detailed explanation of each component of the ABCDEFGH approach.
Hyperkalaemia is a life-threatening dyselectrolytaemia which is characterized by elevated serum potassium levels. It needs a systematic and overarching approach to effectively manage a case of hyperkalaemia. We propose a structured A-to-H approach to guide clinicians in managing hyperkalaemia, ensuring that no critical aspect is neglected or inadvertently missed. This approach involves Analytical accuracy, Background, Clinical context, Diagnosis and drugs, Evaluation, Follow-up, Guidelines adherence, and Health education. With this article, we reiterate the need to properly assess and promptly manage a case of hyperkalaemia in various clinical settings, providing detailed explanation of each component of the ABCDEFGH approach.
Related Concept Videos
Antihypertensive Drugs: Potassium-Sparing Diuretics
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Heart Failure Drugs: Inotropic Agents
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Nonlinear Pharmacokinetics: Overview
Nonlinearity can arise due to the saturation of plasma protein-binding or...

